Print page Share page

The news releases listed below were believed to be accurate in all material respects at the time of original issuance. Please note that we do not intend, and assume no obligation, to update, correct or otherwise modify any of these press releases for events that occur subsequent to the original release date. We suggest you review the more recent press releases in order to receive the most current information made available by ARIAD.

Press Releases

View All

ARIAD Announces Full Enrollment in Phase 2 ALTA Trial of Brigatinib
9/15/15 at 7:35 am ET

ARIAD Announces First Patient Treated in Phase 2 Dose-Ranging Optic Trial of Iclusig (Ponatinib)
8/10/15 at 7:35 am ET

If you are a member of the media and you would like to arrange an interview or learn more about ARIAD, please contact Liza Heapes, Senior Manager, Corporate Communications, at 617-494-0400 or

Our Corporate Brochure

A shared commitment to patients and each other.

You are now leaving this website. If you would like to continue, click Continue.